Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429)::porcine reproductive and respiratory syndrome (PRRS) by Health, EFSA Panel on Animal et al.
                          Health, EFSA. P. O. A., (AHAW), W., More, S., Bøtner, A., Butterworth, A.,
Calistri, P., ... Bicout, D. (2017). Assessment of listing and categorisation of
animal diseases within the framework of the Animal Health Law (Regulation
(EU) No 2016/429): porcine reproductive and respiratory syndrome (PRRS).
EFSA Journal, 15(7), e04949-n/a. https://doi.org/10.2903/j.efsa.2017.4949
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.2903/j.efsa.2017.4949
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via EFSA at
http://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2017.4949/abstract . Please refer to any applicable terms of use
of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
SCIENTIFIC OPINION
ADOPTED: 30 June 2017
doi: 10.2903/j.efsa.2017.4949
Assessment of listing and categorisation of animal diseases
within the framework of the Animal Health Law (Regulation
(EU) No 2016/429): porcine reproductive and respiratory
syndrome (PRRS)
EFSA Panel on Animal Health and Welfare (AHAW),
Simon More, Anette Bøtner, Andrew Butterworth, Paolo Calistri, Klaus Depner,
Sandra Edwards, Bruno Garin-Bastuji, Margaret Good, Christian Gortazar Schmidt,
Virginie Michel, Miguel Angel Miranda, Søren Saxmose Nielsen, Mohan Raj,
Liisa Sihvonen, Hans Spoolder, Jan Arend Stegeman, Hans-Hermann Thulke, Antonio Velarde,
Preben Willeberg, Christoph Winckler, Francesca Baldinelli, Alessandro Broglia,
Beatriz Beltran Beck, Lisa Kohnle, Joana Morgado and Dominique Bicout
Abstract
Porcine reproductive and respiratory syndrome (PRRS) has been assessed according to the criteria of
the Animal Health Law (AHL), in particular criteria of Article 7 on disease proﬁle and impacts, Article 5
on the eligibility of PRRS to be listed, Article 9 for the categorisation of PRRS according to disease
prevention and control rules as in Annex IV and Article 8 on the list of animal species related to PRRS.
The assessment has been performed following a methodology composed of information collection and
compilation, expert judgement on each criterion at individual and, if no consensus was reached before,
also at collective level. The output is composed of the categorical answer, and for the questions where
no consensus was reached, the different supporting views are reported. Details on the methodology
used for this assessment are explained in a separate opinion. According to the assessment performed,
PRRS can be considered eligible to be listed for Union intervention as laid down in Article 5(3) of the
AHL. The disease would comply with the criteria as in Sections 4 and 5 of Annex IV of the AHL, for the
application of the disease prevention and control rules referred to in points (d) and (e) of Article 9(1).
The animal species to be listed for PRRS according to Article 8(3) criteria are domestic pigs and wild
boar.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
The background and Terms of Reference (ToR) as provided by the European Commission for the
present document are reported in Section 1.2 of the scientiﬁc opinion on the ad hoc methodology
followed for the assessment of the disease to be listed and categorised according to the criteria of
Article 5, Annex IV according to Article 9, and Article 8 within the Animal Health Law (AHL) framework
(EFSA AHAW Panel, 2017).
1.2. Interpretation of the Terms of Reference
The interpretation of the ToR is as in Section 1.2 of the scientiﬁc opinion on the ad hoc
methodology followed for the assessment of the disease to be listed and categorised according to the
criteria of Article 5, Annex IV according to Article 9, and 8 within the AHL framework (EFSA AHAW
Panel, 2017).
The present document reports the results of assessment on porcine reproductive and respiratory
syndrome (PRRS) according to the criteria of the AHL articles as follows:
• Article 7: PRRS proﬁle and impacts
• Article 5: eligibility of PRRS to be listed
• Article 9: categorisation of PRRS according to disease prevention and control rules as in Annex IV
• Article 8: list of animal species related to PRRS.
2. Data and methodologies
The methodology applied in this opinion is described in detail in a dedicated document about the
ad hoc method developed for assessing any animal disease for the listing and categorisation of
diseases within the AHL framework (EFSA AHAW Panel, 2017).
3. Assessment
3.1. Assessment according to Article 7 criteria
This section presents the assessment of PRRS according to the Article 7 criteria of the AHL and
related parameters (see Table 2 of the opinion on methodology (EFSA AHAW Panel, 2017)), based on
the information contained in the fact-sheet as drafted by the selected disease scientist (see section 2.1
of the scientiﬁc opinion on the ad hoc methodology) and amended by the AHAW Panel.
3.1.1. Article 7(a) Disease Proﬁle
3.1.1.1. Article 7(a)(i) Animal species concerned by the disease
Susceptible animal species
Parameter 1 – Naturally susceptible wildlife species (or family/orders)
Eurasian wild boar (Sus scrofa): Natural infections reported from many EU Member States (MSs)
(Bonilauri et al., 2006; Vengust et al., 2006; Reiner et al., 2009; Montagnaro et al., 2010; Wu et al.,
2011b; Boadella et al., 2012; Touloudi et al., 2015; Vilcek et al., 2015; Stankevicius et al., 2016).
Also present in wild boar/feral pigs in Asia and Americas (Gipson et al., 1999; Wu et al., 2011a,
2012; Choi et al., 2012; Cano-Manuel et al., 2014; McGregor et al., 2015).
Parameter 2 – Naturally susceptible domestic species (or family/orders)
Domestic pig (Sus scrofa domesticus) (Albina, 1997).
Parameter 3 – Experimentally susceptible wildlife species (or family/orders)
Eurasian wild boar (Sus scrofa): In Europe, the course of disease is assumed the same as for PRRS
in domestic pigs, although a study with highly pathogenic (HP) Type 2 strain of Porcine reproductive
and respiratory syndrome virus (PRRSV) did result in more severe disease in wild pigs, compared to
domestic pigs (Do et al., 2015b).
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Early experiments of infection in bird species initially claimed productive infection in Mallard ducks
(Anas platyrhynchos) (Zimmerman et al., 1997). Later work (Trincado et al., 2004) failed to reproduce
the work and the claims of (Zimmerman et al., 1997) are now considered ﬂawed.
Parameter 4 – Experimentally susceptible domestic species (or family/orders)
Domestic pig (Sus scrofa domesticus) (Albina, 1997).
Reservoir animal species
Parameter 5 – Wild reservoir species (or family/orders)
Eurasian wild boar (Sus scrofa).
Natural infections and serological evidence of exposure in wild boar have been widely reported
throughout Europe (Albina, 1997; Zupancic et al., 2002; Bonilauri et al., 2006; Vengust et al., 2006; Reiner
et al., 2009; Boadella et al., 2012; Touloudi et al., 2015; Vilcek et al., 2015; Stankevicius et al., 2016) and
also in Asia, although fewer studies have been carried out (Wu et al., 2011a, 2012; Choi et al., 2012).
Parameter 6 – Domestic reservoir species (or family/orders)
Domestic pig (Sus scrofa domesticus). The virus may persist for some weeks after apparent
recovery. In smaller herds, the virus is likely to be eventually eliminated, but in larger herds (> 250
sows), there is a greater likelihood of virus persistence within the herd (Evans et al., 2008). There is
evidence that boars may excrete virus via semen for up to 90 days (Christopher-Hennings et al., 1995)
and some claims have been made of a ‘carrier’ status, with virus persisting in tissues for more than
100 days (Horter et al., 2002) but is unclear whether such animals are infectious to in-contact animals.
3.1.1.2. Article 7(a)(ii) The morbidity and mortality rates of the disease in animal
populations
Morbidity
Parameter 1 – Prevalence/ Incidence
A survey of veterinary practitioners in European countries (de Paz et al., 2015) was undertaken to
assess PRRS prevalence in European pig holdings based on the farmers’ perceptions. Swine veterinary
practitioners (515 veterinarians in 11 countries) were asked to estimate the percentage of the animals
under his or her supervision that were PRRS-positive. On average, PRRS was estimated to be present
in 71% of sows and in 68% of weaned or growing pigs. While on average, clinical cases of the disease
were estimated to occur in 17% of sows and in 23% of weaned or growing pigs. However, the
prevalence of clinical signs due to PRRSV in sows in particular varied widely by country, from a high of
47% reported from Italy to just 4% for Russia.
An early Dutch study demonstrated that 23% of 8–9 week-old pigs were PRRSV seropositive
(Nodelijk et al., 1997) and a more recent seroprevalence study in Spain revealed that the percentage
of PRRSV seropositive herds was over 85% for sows, around 80% for fatteners and around 50% for
boar studs (Lopez-Soria et al., 2010).
Parameter 2 – Case-morbidity rate (% clinically diseased animals out of infected ones)
The case-morbidity rate can vary greatly and a number of factors may be involved. These include
the age of the pigs, the strain of the virus and the presence of other pathogens (Done and Paton,
1995; Solano et al., 1998; Brockmeier et al., 2001; Opriessnig et al., 2011).
In piglets, there is often an increase in neonatal diarrhoea and respiratory infections such as Gl€asser’s
disease. In weaners and growing pigs, the only clinical signs may be a period of slight inappetence,
perhaps with coughing and some wasting. Sometimes, disease is inapparent. In sows, there may be
inappetence, mild fever, abortions and respiratory signs, and in a small percentage of animals, they may
show a transient ‘blueing’ of the ears. Around 10–15% of sows may farrow slightly early and there may
also be an increase in delays in returning to heat (Meredith, 1995). Weak-born and still-born piglets, with
associated pre- and post-weaning mortalities are often a predominant sign and losses can exceed 75%,
particularly in large farms (Pejsak et al., 1997; Goldberg et al., 2000). In boars, sneezing and coughing,
depression, low-grade fever and inappetence, and occasionally blueing of ears in a small percentage of
affected animals occur. There are no reports of loss of libido, but some reduction in ejaculate volume has
been recorded (Meredith, 1995). A table of morbidity rates and clinical signs is provided in Table 1, based
on early studies of the disease in the UK (Meredith, 1995).
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Mortality
Parameter 3 – Case-fatality rate
In a study of a PRRS outbreak in a large swine farm in Poland (Pejsak and Markowska-Daniel,
1997), the following was observed: during the ﬁrst month after onset of the outbreak, 25.6% of sows
farrowed before 110 days of pregnancy, the percentage of mummiﬁcations was 21.7%, the
percentage of piglets that died before weaning was 43.3%, losses among fatteners and weaners were
15%,. Prior to the occurrence of PRRS, the percentage of sows that farrowed before term was 1.4%,
the piglets’ mortality rate did not exceed 6%, and losses among fatteners and weaners were lower
than 3.5%. The average production of weaned piglets per sow per year dropped from 21.1 prior the
outbreak to 18.1 during the outbreak. The farrowing rate dropped from 80.5% to 47.7% and even
12 months after onset of the outbreak did not reach the level found before the outbreak.
In the USA, a study of 34 nursery units, where PRRS had been present for some time, reported mortalities
of approximately 10% (Dee et al., 1997a) prior to application of various depopulation interventions.
A study in Thailand of aborted and mummiﬁed foetuses and stillborn piglets revealed that 67%
(60/89) of the specimens contained PRRS virus. The virus was found in 66% (21/32) of aborted
foetuses, 63% (19/30) of mummiﬁed foetuses and 74% (20/27) of stillborn piglets. Type 1, Type 2
and mixed Types of PRRS virus were detected in 19% (17/89), 26% (23/89) and 23% (20/89) of the
specimens, respectively. The vaccination status of herds had no signiﬁcant effect on the percentage of
herd with active virus circulation (Olanratmanee et al., 2015). Stillbirth levels were reported to increase
up to 30% and 10–15% of a litter may die in the last 3–4 weeks of pregnancy and be born
mummiﬁed. Piglet mortality may peak as high as 70% in weeks 3 or 4 after the onset of clinical signs
and only returns to normal levels after 8–12 weeks. The reproductive problems may persist for 4–8
months before returning to normal (Olanratmanee et al., 2015).
3.1.1.3. Article 7(a)(iii) The zoonotic character of the disease
Presence
Parameter 1 – Report of zoonotic human cases (anywhere)
There is no evidence of human infection with PRRSV.
3.1.1.4. Article 7(a)(iv) The resistance to treatments, including antimicrobial resistance
Parameter 1 – Resistant strain to any treatment even at laboratory level
No treatments for PRRSV infection have been described, beyond administration of antibiotics to combat
secondary bacterial infections associated with the respiratory disease often associated with PRRSV infection.
Table 1: Acute PRRS: clinical signs and effects based on European data
Clinical sign or effect % of farms affected % of animals affected on affected farm
Primary inﬂuenza-like illness
Fever 50 1–10
Blue extremities 69 1–5
Also: inappetence, conjunctivitis, eyelid oedema, depression, respiratory signs, haemorrhage, bruising
Secondary effects
Pre-weaning mortality 100 10–40
Post-weaning mortality 100 1–10
Sudden death 44 1–2
Pneumonia (growers) 50 1–30
Reproductive effects
Abortions 44 1–2
Premature litters 100 1–20
Stillborn piglets 100 7–35
Returns to service 69 10–50
Also: mummiﬁcation, weak-born piglets, splay-legged, periorbital oedema, anoestrus
Source: Meredith (1995)
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3.1.1.5. Article 7(a)(v) The persistence of the disease in an animal population or the
environment
Animal population
Parameter 1 – Duration of infectious period in animals
PRRSV has the ability to establish infections with extended periods of viraemia and excretion,
beyond that normally seen with acute virus infections. Pigs are usually infectious between days 3 and
40 days post-infection, but can remain so for several months (OIE, online a). A longitudinal study in
conventional piglets with a Type 1 strain of PRRSV, demonstrated lungs and alveolar macrophages to
be PRRSV positive by immunohistochemistry method (IHC) and virus isolation until 35 days post-
infection (Duan et al., 1997). A similar study, using PRRSV Type 2 in SPF piglets, demonstrated PRRSV
to be detectable by polymerase chain reaction (PCR) in serum for 5 weeks and oral ﬂuid for 4 weeks
post-infection (Prickett et al., 2008). In breeding age gilts, the duration of shedding has been
demonstrated to be relatively short, at around 14 days (Batista et al., 2002).
See also Parameter 3 below, concerning carrier status.
Parameter 2 – Presence and duration of latent infection period
For the purposes of international trade, the Draft OIE Code Chapter deﬁnes the incubation period
for of PRRS as 14 days (OIE, online a). A true latent infection (beyond the normal incubation time),
following infection of na€ıve animals has not been described for PRRS virus.
Parameter 3 – Presence and duration of the pathogen in healthy carriers
In a study of fattening pigs infected at three weeks of age, viable virus was demonstrated in 10 of
11 pigs, 105 days post-inoculation (dpi) (Horter et al., 2002). Oropharyngeal samples from intranasally
infected 4-week-old pigs were virus isolation (VI) positive up to 84 dpi and, in one animal, up to 157
dpi, 134 days after the last isolation of virus from serum from this animal (Wills et al., 1997b).
Virus may persist for over 100 days in the semen of recovered boars (Albina, 1997) and has been
demonstrated to be transmissible by this route (Prieto et al., 1997). The duration of excretion may
vary: In boars infected with Type 2 PRRSV, viable virus was detected up to 43 days in semen
(Swenson et al., 1994). In a more comprehensive study, the maximum number of days (+/ SD) for
the duration of PRRSV shedding in semen was determined to be 51 +/ 26.9 days, in Landrace boars.
Other breeds were infectious for a shorter period, but the differences were not signiﬁcant
(Christopher-Hennings et al., 2001). It is recognised as a signiﬁcant pathway for introduction of
disease via artiﬁcial insemination (Maes et al., 2008). A review of PRRSV in boars is also available
(Prieto and Castro, 2005).
Environment
Parameter 4 – Length of survival (dpi) of the agent and/or detection of DNA in selected matrices (soil,
water, air) from the environment (scenarios: high and low T)
A study of PRRSV survival in soil at ambient temperatures (10–16°C) showed virus to survive for
only 1 or 2 h (Dee et al., 2003). The virus was isolated from water kept at 25–27°C for up to 11 days
(Pirtle and Beran, 1996), and in swine lagoon efﬂuent kept at 4°C for 8 days (Dee et al., 2005).
Survival in air is very variable and a factor of UV254 dose, also with dependencies on temperature and
relative humidity, with humidities of > 80% signiﬁcantly increasing virus survival, regardless of
temperature (Cutler et al., 2012). These authors calculated the dose of UV254 required to inactivate
99.9% of airborne PRRS virus as (0.121 mJ/area2 per half-life) 9 (10 half-lives) = 1.21 mJ/area2.
An early study (Bloemraad et al., 1994) demonstrated that, in tissue culture medium, the virus is
stable for prolonged periods of storage at 70°C and 20°C. At higher temperatures, the half-life of
PRRSV is 140 h at 4°C, 20 h at 21°C, 3 h at 37°C and 6 min at 56°C. The half-life of PRRSV, both at
4°C and 37°C, varies considerably with pH; at 4°C and pH 6.25, it has a maximum half-life of 50 h and
at 37°C and at pH 6.0, a maximum half-life of 6.5 h. However, increasing or decreasing the pH of the
medium rapidly decreases the half-life of PRRSV at both temperatures.
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3.1.1.6. Article 7(a)(vi) The routes and speed of transmission of the disease between
animals, and, when relevant, between animals and humans
Routes of transmission
Parameter 1 –Types of routes of transmission from animal to animal (horizontal, vertical)
PRRSV has been recovered from a variety of porcine secretions and excretions including blood,
semen, saliva, faeces, aerosols, milk, and colostrum (Albina, 1997; Wills et al., 1997a; Prieto and
Castro, 2005). Faecal shedding remains a highly debated issue as studies report the presence of
PRRSV in faeces from 28 to 35 dpi (Yoon et al., 1993), whereas others report no detection of virus in
faecal samples (Wills et al., 1997a).
Horizontal transmission most commonly occurs by close contact between pigs or by exposure to
contaminated body ﬂuids (semen, virus-contaminated blood, secretions, contaminated needles,
coveralls, and boots). Social behaviour and pig-to-pig interactions are important in direct transmission,
particularly the aggressive behaviours (scraping and biting) associated with establishing social order,
where blood and saliva may be exchanged. Other behaviours that result in exchange of blood and
saliva, eg; tail-biting and ear-biting, may also play a role in transmission. Airborne transmission has
also been demonstrated, both experimentally and in the ﬁeld (Brockmeier and Lager, 2002; Kristensen
et al., 2004; Dee et al., 2009; Otake et al., 2010). Transmission by insects has been proposed, but the
importance of its role in ﬁeld transmission of PRRS is unknown (Pitkin et al., 2009).
Vertical transmission from pregnant sows to their piglets can occur in utero, with infection and
consequent fetal and neonatal death particularly likely following infection in late gestation (Prieto et al.,
1996, 1997; Mengeling et al., 1998a,b; Rowland, 2010).
A review of PRRSV transmission (Desrosiers, 2011) concluded that, in cases of introduction of PRRS
to PRRS-negative farms, between 81% and 100% were via an indirect route, which reﬂects both the
efﬁcacy of biosecurity procedures associated with breeding and pig movements and the challenges
that still need to be overcome in preventing PRRSV infections by other routes.
Parameter 2 – Types of routes of transmission between animals and humans (direct, indirect, including
food-borne)
Not applicable. PRRSV has never been known to infect humans.
Speed of transmission
Parameter 3 – Incidence between animals and, when relevant, between animals and humans
The virus may spread rapidly among na€ıve pigs in close proximity, with younger animals being both
more susceptible, with higher rates of excretion and seroconversion (Nodelijk et al., 2003). In the case
of piglets, the key consequence of PRRSV infection is a respiratory disease which main associated
lesion is interstitial pneumonia. The severity of the respiratory signs is determined mostly by the
participation of other complicating agents, particularly bacteria although interactions with other viruses
(e.g. Porcine Circovirus 2) have been demonstrated (Thacker et al., 1999; Thanawongnuwech et al.,
2000; Szeredi and Szentirmai, 2008) and can result in very rapid spread among littermates and
housemates (Palzer et al., 2008; Tousignant et al., 2015). Also, differences among isolates with regard
to the severity of the respiratory disease exist (Mengeling et al., 1996).
Parameter 4 – Transmission rate (beta) (from R0 and infectious period) between animals and, when
relevant, between animals and humans
Due to the nature of infection with this virus, it is difﬁcult to assign a transmission rate for PRRSV.
This is because the course of infection, the quantity and the proﬁle of virus excretion all vary over
time. Excretion and therefore the transmission is dependent on a number of factors, including the
strain/virulence of the virus involved, the infection dose, and route, as well as the age, immune
response and presence of other pathogens in the pig. In particular, highly virulent viruses seem to be
much more transmissible by the airborne route (Cho et al., 2007).
In an experimental study in SPF piglets, excretion increased from 7 to 14 dpi and then decreased
slowly until 42 dpi, allowing the authors to model the time-dependent infectiousness by a log normal-
like function with a latency period of 1 day, indicating an estimated basic reproduction ratio, R0 of 2.6,
with a range of between 1.8 and 3.3 during the infectious period (Charpin et al., 2012).
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In an analysis of a PRRS outbreak in a breeding herd in the Netherlands, the basic reproduction ratio1
(R0) was calculated to be 3.0 (95% conﬁdence interval 1.5–6.0), based on the assumptions that the
infectious period lasts 56 days and that no lifelong immunity exists after infection (Nodelijk et al., 2000).
In an experimental study, demonstrating airborne transmission, a seroconversion in 94–100% of
the pigs were demonstrated in each of three individual groups of previously PRRSV-seronegative pigs
within 3 weeks after introduction of infection (Kristensen et al., 2004).
3.1.1.7. Article 7(a)(vii) The absence or presence and distribution of the disease in the
Union, and, where the disease is not present in the Union, the risk of its
introduction into the Union
Presence and distribution
Parameter 1 – Map where the disease is present in EU
Parameter 2 – Type of epidemiological occurrence (sporadic, epidemic, endemic) at MS level
PRRS is widespread and endemic in most Member States of the European Union (EU) and is
considered absent in only four countries (Table 2): Norway, Sweden, Finland and Switzerland (Baekbo
and Kristensen, 2015). Based on a short questionnaire by these researchers, mailed to 20 EU countries
(response rate 50%), Type 1 (EU strain) is the most prevalent, and is the only serotype in most
countries, whereas Type 2 (US strain) is known to be present in, e.g. Austria, Denmark, Germany,
Hungary, Lithuania, the Netherlands and Poland.
Figure 1: Map of PRRS presence in EU
Table 2: PRRS status in EU Member States and adjoining countries
Country Present? Genotypes reported Reference
Austria Yes Type 1 and Type 2 Indik et al. (2005), Stadejek et al. (2013)
Belgium Yes Type 1 (and Type 2?) Houben et al. (1995b)
Bulgaria Yes Type 1? Mortrovski et al. (2009)
Croatia Yes Type 1? Prpic et al. (2014)
1 The basic reproductive ratio R0 is deﬁned as the expected number of secondary infections arising from a single individual
during his or her entire infectious period, in a population of susceptibles.
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Due to a general lack of systematic surveillance in most countries, the true prevalence of infected
herds is unknown, but based on estimations, is expected to be 25–50%, in e.g. Denmark and
Romania, 50–75% in, e.g. Germany, Greece and Austria and 80–95% in, e.g. Italy and Spain.
A HP strain of PRRSV Type 2 (HP-PRRS) has been described in Asia, but this has never been detected
in the EU. A new strain of PRRSV is present in some non-EU eastern European countries, putatively
named PRRSV Type 1, subtype 3, which is claimed to have higher virulence than conventional European
strains (Morgan et al., 2013; Weesendorp et al., 2014). Its precise distribution is unknown.
Risk of introduction
Infection is already present in MSs.
3.1.1.8. Article 7(a)(viii) The existence of diagnostic and disease control tools
Diagnostic tools
Parameter 1 – Existence of diagnostic tools
A number of commercial diagnostic kits are available to detect antibody to PRRSV. Additionally,
specialist laboratories can provide indirect ﬂuorescent antibody (IFA) tests for immunoglobulin M (IgM),
which can be useful for detecting evidence of active infection in a herd.
The serological tests used for PRRS in diagnosis (Collins et al., 1996) are provided in Table 3.
Country Present? Genotypes reported Reference
Cyprus Not reported
Czech Republic Yes Type 1 Indik et al. (2000)
Denmark Yes Type 1 and Type 2 Kvisgaard et al. (2013a,b)
Estonia Not reported
Finland No Rautiainen et al. (2001), Niederwerder and Rowland
(2016), EVIRA (online)
France Yes Type 1 Baron et al. (1992)
Germany Yes Type 1 and Type 2 Greiser-Wilke et al. (2010)
Greece Yes Type 1? Alexopoulos et al. 2005)
Hungary Yes Type 1 and Type 2 Stadejek et al. (2013), Balint et al. (2015)
Ireland Yes Anonymous (online a)
Italy Yes Type 1 Pesente et al. (2006), Franzo et al. (2015)
Latvia Yes Type 1 Stadejek et al. (2013)
Lithuania Yes Type 1 and Type 2 Stadejek et al. (2002, 2013)
Luxembourg Yes Type 1 Schroder and Bemerich (2003)
Malta Not reported
Netherlands Yes Type 1 and Type 2 Wellenberg et al. (2004)
Poland Yes Type 1 and Type 2 Stadejek et al. (2013)
Portugal Yes Type 1 only?
Romania Yes Type 1 Zaulet et al. (2012)
Slovakia Yes Type 1 and Type 2 Jackova et al. (2013)
Slovenia Yes Type 1 Toplak et al. (2012)
Spain Yes Type 1 Mateu et al. (2003), Lopez-Soria et al. (2010)
Sweden No Rautiainen et al. (2001), Niederwerder and Rowland
(2016)
United Kingdom Yes Type 1 Frossard et al. (2012)
Norway No Rautiainen et al. (2001), Grøntvedt et al. (2014),
Niederwerder and Rowland, (2016)
Russia Yes Type 1 Bulgakov et al. (2014)
Serbia Yes Type 1 Balka et al. (2010), Petrovic et al. (2011)
Switzerland No Baekbo and Kristensen (2015), Niederwerder and
Rowland (2016)
Note: Where virus type is marked ‘?’, type is assumed, based on neighbouring countries or because vaccine of that type is
licensed in that country.
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A few serological tests (enzyme-linked immunosorbent assay (ELISA) and immunoperoxidase
monolayer assay (IPMA)) have been developed to differentiate between infection with PRRS Type 1
and 2 (Sorensen et al., 1998; Botner et al., 2000). For virus detection, a small number of commercial
PCR kits are now available (e.g. QiaGen, Life Technologies, Bioingentech, etc.), some of which can
differentiate between PRRS Type 1 and 2.
Virus isolation of PRRS Type 1 virus is particularly challenging, since isolates generally do not grow
in permanent cell lines, so primary cultures are used, derived from alveolar macrophages harvested
from piglets from negative herds. This makes the test very expensive and only used in research.
A number of specialist laboratories throughout the EU can provide diagnostic service and virus
characterisation.
Control tools
Parameter 2 – Existence of control tools
PRRS outbreaks are generally controlled by a combination of husbandry and vaccination (Dee and
Joo, 1997).
a) A herd management programme involving:
1) Cross fostering before 24 h.
2) No movement of pigs between sections (all in/all out and disinfection).
3) Euthanasia of unthrifty piglets.
4) No contact between weaned pigs and sows.
b) A vaccination programme, involving
1) Moving the oldest gilts to the breeding unit.
2) Immediately vaccinating these gilts with a PRRS modiﬁed live vaccine appropriate to the
prevailing genotype.
3) Vaccinating the rest of the gilts the same day.
4) Initiating a quarantine period for 12 weeks thereafter.
Table 3: Serological tests used for diagnosis of PRRS
Serological tests for porcine reproductive and respiratory syndrome (PRRS) virus
Serological
test
Antibody
ﬁrst
detected
Peak
antibody
titre
Decline in
antibody
titre
Antibody
undetectable
at
Positive
titre
Sensitivity Speciﬁcity
Indirect
ﬂuorescent
antibody
(IFA) (detects
IgG)
7–11 days
PI(a)
30–50
days PI
Rapid 4–6 months
PI
≥ 1:16 or
≥ 1:20(b)
? High
Indirect
ﬂuorescent
antibody
(IFA) (detects
IgM)
5 days PI
in
3-week-
old pigs;
7 days PI
in sows
14 days
PI
Very
rapid
28 days
PI in
3-week-
old pigs;
21 days
PI in sows
≥ 1:16 or
≥ 1:20(b)
? ?
ELISA 9–13 days
PI
30–50
days PI
Rapid 4 to ≥ 10
months PI
S:P
ratio
≥ 0.4
High(c) High
Serum
neutralisation
9–28 days
PI
60–90
days PI
Gradual ≥ 1 year PI ≥ 1:4 Low High
ELISA: enzyme-linked immunosorbent assay; IgM: immunoglobulin M; IgG: immunoglobulin G.
(a): PI = post-infection.
(b): Depends on the initial dilution used in the IFA test.
(c): Sensitivity (100%, 35/35 samples) and speciﬁcity (99.5%, 413/415 samples); personal communication, Michael L. Synder,
IDEXX Laboratories Inc.Source: Collins et al. (1996).
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c) Herds are generally protected thereafter by:
1) Vaccination and quarantine of all new pigs.
2) Maintenance of the rules in a) above.
3) Vaccination of all piglets with Modiﬁed Live Vaccine (MLV) at 4–6 weeks.
4) Sows may be vaccinated with a killed vaccine, if considered necessary.
In some circumstances, where disease has been present for some time, a total depopulation of the
nursery units has been prescribed (Dee et al., 1997b).
For boars, a fairly recent review of the subject (Althouse and Rossow, 2011) concluded that
representative screening of boar-semen donors should be carried out daily for PRRSV via PCR prior to
extended semen distribution and use. They also recommended serial pre-screening of boars prior to
introduction into the resident herd, ﬁltration of air entering the stud and biosecurity were best
methods of control.
There has been much controversy concerning live modiﬁed vaccines. PRRS virus is highly mutable
and there have been several recorded cases spread from vaccinated to unvaccinated animals and of
reversion to virulence (Botner et al., 1997; Nielsen et al., 2001). Additionally, boars are known to
excrete vaccine virus in semen, representing an additional risk of spread (Nielsen et al., 1997).
Manufacturers stress the importance of vaccinating all animals in a herd simultaneously and
maintaining biosecurity and also of the potential hazards of vaccinating boars.
3.1.2. Article 7(b) The impact of diseases
3.1.2.1. Article 7(b)(i) The impact of the disease on agricultural and aquaculture
production and other parts of the economy
The level of presence of the disease in the Union
Parameter 1 – Number of MSs where the disease is present
PRRS is widespread and endemic in most Member States of the EU and is absent only in four
European countries: Norway, Sweden, Finland and Switzerland (Baekbo and Kristensen, 2015). Based
on a short questionnaire by these researchers, mailed to 20 EU countries (response rate 50%), Type 1
(EU strain) is the most prevalent and only serotype in most countries.
The loss of production due to the disease
Parameter 2 – Proportion of production losses (%) by epidemic/endemic situation
The cost of the PRRSV infection in Europe seems not to be very well estimated in most countries.
The economic impact of this disease, under ﬁeld conditions, is often overlooked and the few studies
available were often carried out in the USA (Fraile, 2012). In the US, the total annual economic impact
of PRRS on US swine producers has been estimated at USD 66.75 million in breeding herds and USD
493.57 million in growing-pig populations (Neumann et al., 2005).
In na€ıve herds in Poland, production losses have been observed as high as 10–20% in weaners and
1–3% of adults. Depending on the stage of gestation, pregnant sows may farrow early, with resultant
heavy piglet losses, with mortalities of as high as 75% recorded in animals up to ﬁve weeks of age. In
addition expenses dealing with preventing and treating secondary infections, during the 12 months
after the outbreak were on average 60% higher than, those found, during the previous year (Pejsak
et al., 1997).
In a Dutch study (Nieuwenhuis et al., 2012), an outbreak of PRRSV reduced the number of sold
pigs per sow by 1.7. The economic loss varied between €59 and €379 per sow per 18-week period
outbreak. The mean loss per sow per outbreak was €126. The costs after the outbreak varied
signiﬁcantly from €3 to 160 per sow, due to the different methods used by farmers to tackle PRRSV
outbreaks.
In an endemic situation, however, the scale of losses will depend on the timing of any re-
introduction of virus and the similarity to viruses causing past infection (Molitor et al., 1997; Murtaugh
et al., 2002; Mateu and Diaz, 2008). Immunity is often poor and transient, both to ﬁeld infection and
to vaccines (Lyoo, 2015). When comparing a large number of chronically infected herds to non-
infected herds, Danish studies showed only a marginally reduction in productivity. The piglet mortality
was 0.8–0.9%-point higher and the nursery mortality was 0.4%-point higher in infected herds. No
difference was seen in mortality among ﬁnishers (Baekbo and Kristensen, 2015).
AHL assessment on porcine reproductive and respiratory syndrome (PRRS)
www.efsa.europa.eu/efsajournal 12 EFSA Journal 2017;15(7):4949
3.1.2.2. Article 7(b)(ii) The impact of the disease on human health
Not applicable – humans are not susceptible to infection with PRRS virus.
3.1.2.3. Article 7(b)(iii) The impact of the disease on animal welfare
Parameter 1 – Severity of clinical signs at case level and related level and duration of impairment
Infection of pregnant sows can lead to abortion, through replication of virus in endometrial/
placental tissues (Karniychuk and Nauwynck, 2013). In utero infection may also lead to subsequent
death of fetuses, which are born mummiﬁed or partially autolysed, along with high rates of weak born
and neonatal deaths among piglets born live (Rossow, 1998). In nursery pigs, breathing difﬁculties,
fever and inappetence are common and respiratory disease can be severe, complicated by secondary
infections, which may continue for several weeks and will result in further high rates of mortality. This
may continue into the ﬁnisher stage (Young et al., 2010). Uncomplicated infections with HP strains of
PRRSV will cause fever, anorexia, dyspnoea and tachypnoea in piglets, with associated high mortality
(Liu et al., 2015).
Adult pigs may show some or few clinical signs, apart from inappetance and a mild, transient fever.
HP strains of PRRS may, however, cause high fever and pneumonia in adults which may continue for
some weeks (Li et al., 2007).
3.1.2.4. Article 7(b)(iv) The impact of the disease on biodiversity and the environment
Biodiversity
Parameter 1 – Endangered wild species affected: listed species as in CITES and/or IUCN list
In northern India, there is considerable concern about the fate of the pygmy hog (Porcula salvania/
Sus salvanius), consequent with the appearance of PRRS in the region. It is a critically endangered
suid, now only found in Assam, with a current population of about 150 individuals (Prof Nagendra
Barman, Assam Agricultural University (Pers. Comm.).
The susceptibility of other IUCN Red Listed Asian suids (bearded and warty hogs Sus spp.,
Babyrousa babyrussa spp.), African suids (warthogs, Phacochoerus spp.; giant forest hog –
Hylochoerus meinertzhageni, red river hog – Potamochoerus larvatus; bushpig – Potamochoerus
porcus) and South/Central American suids (peccaries – Tayassu spp.) is unknown.
Parameter 2 – Mortality in wild species
Unknown. It is assumed that, at individual animal level, the mortality in wild boar (Sus scrofa) is
the same as for domestic pigs (Sus scrofa domesticus), though the roaming nature, animal density and
herd sizes of wild boar ‘sounders’ is much smaller than may be found in pig rearing units, so overall
mortalities are likely to be much less.
Environment
Parameter 3 – Capacity of the pathogen to persist in the environment and cause mortality in wildlife
PRRSV is regularly detected in wild boar populations. A comparative genotyping study of isolates
from wild boar and domestic pigs in the same region concluded there was only a weak relationship
between viruses found in the two populations (Reiner et al., 2009). This suggests that PRRS in wild
boar is a self-sustaining infection, with likely mortalities in individual animals as for domestic pigs.
3.1.3. Article 7(c) Its potential to generate a crisis situation and its potential use
in bioterrorism
Parameter 1 – Listed in OIE/CFSPH classiﬁcation of pathogens
PRRS is an OIE-listed disease. It is also listed in the OIE Manual Diagnostic Tests and Vaccines for
Diseases of Terrestrial Animals, but not in the OIE Code – a Chapter is in preparation. It is listed on
the CFSPH website, but no classiﬁcation is given, nor is there a Disease Factsheet for this disease.
Parameter 2 – Listed in the Encyclopaedia of Bioterrorism Defence of Australia Group
PRRSV is not listed in the Australia Group List of Human and Animal Pathogens and Toxins for
Export Control. (Anonymous, online b).
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Parameter 3 – Included in any other list of potential bio- agro-terrorism agents
No speciﬁc lists identiﬁed, but PRRSV has been considered, in the context more insidious forms of
agroterrorism, by virtue of its relatively prolonged infection and slower spread, compared to listed
pathogens (Keeling and Rohani, 2011).
3.1.4. Article 7(d) The feasibility, availability and effectiveness of the following
disease prevention and control measures
3.1.4.1. Article 7(d)(i) Diagnostic tools and capacities
Availability
Parameter 1 – Ofﬁcially/internationally recognised diagnostic tool, OIE certiﬁed
No diagnostic kits for PRRS are listed on the Register of diagnostic kits certiﬁed by the OIE as
validated as ﬁt for purpose.
The OIE Manual lists the following tests for the purposes detailed in Table 4:
Effectiveness
Parameter 2 – Se and Sp of diagnostic test
Antibody ELISA for serum have very high sensitivity, generally considered to be 100%. Speciﬁcity
can vary, depending on the manufacturer, with reported ranges of between 90% and 100%. In one
study, differences were also seen between ELISAs, in terms of how early seroconversion could be
detected (Gerber et al., 2014).
In monitoring boar studs, antibody ELISA using oral ﬂuid are reported to have approximately 97%
sensitivity and speciﬁcity (Kittawornrat et al., 2012; Sattler et al., 2015).
The IPMA was the ﬁrst serological test to be used for detection of antibody to PRRS. Comparisons
with commercial ELISAs showed them to be superior to the IPMA, in terms of sensitivity and speciﬁcity
(Drew, 1995; Houben et al., 1995a) and IPMA is now only rarely used.
Table 4: Diagnostic tests for PRRS and their application (OIE, online b)
Method
Purpose
Population
freedom from
infection
Individual
animal
freedom
from
infection
prior to
movement
Contribution to
eradication
policies
Conﬁrmation of
clinical cases
Prevalence of
infection –
surveillance
Immune
status in
individual
animals or
populations
post-
vaccination
Agent identiﬁcation(a)
Virus
isolation
– ++ – +++ – –
RT-PCR +++ +++ +++ +++ ++ –
IHC – – – ++ – –
ISH – – – ++ – –
Detection of immune response(b)
ELISA +++ ++ +++ ++ +++ ++
IPMA ++ ++ ++ + ++ +++
IFA ++ ++ ++ + ++ +++
+++: recommended method; ++: suitable method; +: may be used in some situations, but cost, reliability, or other factors
severely limits its application; –: not appropriate for this purpose.
Although not all of the tests listed as category +++ or ++ have undergone formal validation, their routine nature and the fact that
they have been used widely without dubious results, makes them acceptable.
RT-PCR: reverse-transcription polymerase chain reaction; IHC: immunohistochemistry method; ISH: in-situ hybridisation;
ELISA: enzyme-linked immunosorbent assay; IPMA: immunoperoxidase monolayer assay, IFA: immunoﬂuorescence assay.
(a): A combination of agent identiﬁcation methods applied on the same clinical sample is recommended.
(b): One of the listed serological tests is sufﬁcient.
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Molecular detection tests can be exquisitely sensitive, being able to detect viraemia as early as day
1 of infection (Drigo et al., 2014) and with a large number of multiplex PCRs (Wernike et al., 2013; Hu
et al., 2015) and alternative assays isothermal ampliﬁcation also being described (Park et al., 2016). All
PCRs in general use have sensitivity and speciﬁcity values at, or close to 100%.
Feasibility
Parameter 3 – Type of sample matrix to be tested (blood, tissue, etc.)
The nature of PRRS infection provides a number of diagnostic challenges and the purpose and
timing of the testing will dictate the samples taken and tests applied.
Figure 2 provides a schematic, illustrating the diagnostic tools which may be applied and the
appropriate samples.
3.1.4.2. Article 7(d)(ii) Vaccination
Availability
Parameter 1 – Types of vaccines available on the market (live, inactivated, DIVA, etc.)
No PRRS vaccines are authorised at EU level – they are licensed at national level.
PRRS vaccines available in the EU and globally have been recently reviewed (Charerntantanakul,
2012). An updated table of modiﬁed live vaccines are given in Table 5 and killed/subunit vaccines in
Table 6.
Figure 2: Sampling strategies for diagnosing PRRS and determining the infectious status of herds.
From ‘Global PRRS Solutions’ website: https://www.prrs.com/en/prrs/diagnostics/ (Global
PRRS Solutions, online)
Table 5: Modiﬁed live vaccines available in EU Member States (Note: national licensing applies –
Type 2 vaccines may not be licensed in all MSs)
Vaccine Manufacturer
Genotype
(strain)
For use in Route Dose Program
PRRSFlex EU Boehringer
Ingelheim
Type 1
(94881)
Piglet/nursery/
growing
i/m 1 mL From 17 days of age until
the end of fattening
Ingelvac
PRRS* MLV
Boehringer
Ingelheim
Type 2
(VR-2332)
Gilt/sow i/m 2 mL At any stage of
production
Piglet/nursery/
growing
i/m 2 mL At any stage of
production
Ingelvac
PRRS ATP*
Boehringer
Ingelheim
Type 2
(JA-142)
Nursery/
growing
i/m 2 mL At 3–18 week of age
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Table 6: PRRS vaccines available in EU Member States (vaccines are licensed at national level, so
not all vaccines may be available in all countries)
Vaccine Manufacturer
Genotype/
strain
For
use in
Route Dose Program
Ingelvac
PRRS KV
Boehringer
Ingelheim
Type 1
(P120)
Gilt i/m 2 mL Primary: twice, 3–4 week interval, at any
stage of production
Booster: 60–70 days of each gestation
ReproCyc
PRRS
Boehringer
Ingelheim
Type 1
(94481)
Gilt/sow i/m 2 mL Primary: 2–5 week prior to breeding.
PRRSV na€ıve gilts should not be
vaccinated during pregnancy
Booster: 3 - monthly. Can be used
during pregnancy and lactation
Progressis Merial Type 1
(P120)
Sow i/m 2 mL Primary: twice, 3–4 week interval, at
least 3 week prior to breeding
Booster: 60–70 days of each gestation
Suipravac-
PRRS
Hipra Type 1
(VP-046
BIS or
5710?)
Gilt i/m 2 mL Primary: twice, 3–4 week interval, when
entering the farm
Booster: Follow sows’ vaccination
program
Sow i/m 2 mL Primary: twice, 3–4 week interval, during
pregnancy or lactation
Booster: every 4 months
Suivac
PRRS-INe
and
Suivac
PRRS-IN
Dyntec Type (VD-E1
and VD-E2)
or (VD-E1,
VD-E2 and
VD-A1)
Gilt/sow i/m 2 mL Primary: three times; 1st at 5–6 months
of age, 2nd at 3–4 week after 1st, and
3rd at 6–4 week prior to expected
farrowing
Booster: twice; 1st at 3–4 week after the
farrowing, and 2nd at 6–4 week prior to
the further expected farrowing
Boar i/m 2 mL Primary: twice, 4 week interval, starting
at 6 months of age
Booster: every 4–6 months
Nursery/
growing
i/m 2 mL Three times: 3–4 week interval, starting
at 6–10 week of age
Vaccine Manufacturer
Genotype
(strain)
For use in Route Dose Program
Porcilis PRRS MSD Animal
Health
Type 1 (DV) Gilt/sow i/m or i/d 2/0.2 Primary: 2–4 week prior
to breeding
Booster: 2–4 week prior
to subsequent breeding/
or every 4 months
Piglet/nursery/
growing
i/m or i/d 2/0.2 mL At 2 week of age or
older
Amervac-
PRRS
Hipra Type 1
(VP046)
Nursery/
growing
i/m 2 mL At 4 week of age or
older
Pyrsvac-183 Syva Type 1
(All-183)
Gilt/sow i/m 2 mL Primary: 2–4 week prior
to breeding
Booster: 3–4 week prior
to subsequent breeding
Piglet/nursery/
growing
i/m 2 mL At 2–3 week of age or
older
*: The Type 2 vaccines highlighted in red were formerly used in some EU MSs, but have been found to spread to non-vaccinated
animals and have either never been, or are no longer licensed in many countries.
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The CFSPH List of vaccines for PRRS licensed for use in European countries is provided in
Appendix 3. It does not include some of the more recent vaccines, listed in the tables above.
Parameter 2 – Availability/production capacity (per year)
Unknown, but given the large number of vaccines and manufacturers, supply is not considered an issue.
Effectiveness
Parameter 3 – Field protection as reduced morbidity (as reduced susceptibility to infection and/or to
disease)
Modiﬁed live vaccines are generally effective, short-term, in reducing morbidity and mortalities in
young pigs, although they must be matched to the prevailing genotype (Meng, 2000;
Thanawongnuwech and Suradhat, 2010). Prior vaccination of gilts is also important in preventing in
utero infections. Boar vaccination is also important, but vaccine virus may be excreted in semen so
should be done at least four months before semen collection. The risks of live vaccine virus spread to
unvaccinated animals is a constant risk and should be mitigated by simultaneous vaccination of all pigs
on a farm and strict biosecurity.
Cross-protection between genotypes is generally poor, i.e. Type 1 vaccines are generally only
effective against Type 1 viruses and similarly for Type 2 viruses and vaccines. For Type 2 viruses, a
number of studies of HP strains, which recently emerged in China, have claimed lesser efﬁcacy
afforded by conventional Type 2 vaccines, compared to vaccines derived from the HP genotypes (Tian
et al., 2009; Leng et al., 2012; Do et al., 2015a; Yu et al., 2015). One study claims that a vaccine
derived from HP-PRRS does, however, also protect against conventional Type 2 virus challenge
(Galliher-Beckley et al., 2015). Killed vaccines are much less effective and are generally only used to
maintain some level of immunity in breeding animals.
Parameter 4 – Duration of protection
Duration of protection against homologous strains of virus is usually only around 6 months, even
with animals vaccinated multiple times. For heterologous challenge, protection is very poor.
Feasibility
Parameter 5 – Way of administration
All vaccines should be administered intra-muscularly, often with a diluent also supplied. Porcilis
PRRS may also be given intradermally.
3.1.4.3. Article 7(d)(iii) Medical treatments
Availability
Parameter 1 – Types of drugs available on the market
No drugs speciﬁc to PRRS are produced. For the respiratory disease complex, secondary bacterial
infections may compound the disease initiated by PRRS infection and, in such cases, antibiotics may be
prescribed.
Vitamin E and selenium supplements added to piglet feed, are advocated by many practitioners,
but their value is questionable (Toepfer-Berg et al., 2004).
Vaccine Manufacturer
Genotype/
strain
For
use in
Route Dose Program
Suvaxyn
PRRS
Zoetis Type 1
(218)
Gilt/Sow i/m 2 mL Primary: Can be used in any stage of
pregnancy, but recommended to avoid
vaccination during the 8–10 days before
and after the cover. Repeat every
3–4 months
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3.1.4.4. Article 7(d)(iv) Biosecurity measures
Availability
Parameter 1 – Available biosecurity measures
At farm level, standard biosecurity practice is an essential tool in controlling PRRS. Additionally,
all-in/all-out for batches of piglets with disinfection and empty periods is also practiced. There is an
increasing appreciation of the value of regional coordination in reducing between-farm transmission
(Corzo et al., 2010) and, for pig-dense areas, air ﬁltration is also practiced (Dee et al., 2006; Spronk
et al., 2010). Internationally, restrictions and conditions of importation of pigs and pig products from
outside the EU are detailed in Commission Regulation (EU) No 206/20102 and subsequent
amendments; however, there are no speciﬁc conditions for PRRS speciﬁed in that Regulation.
Effectiveness
Parameter 2 – Effectiveness of biosecurity measures in preventing the pathogen introduction
Where biosecurity practice is rigidly adhered to, it can be very effective in reducing losses due to
PRRS. In some instances, practices which employ strict biosecurity within separate different stages of
production have even succeeded in eliminating PRRS from herds (Yang et al., 2008; Corzo et al., 2010).
Feasibility
Parameter 3 – Feasibility of biosecurity measures
At farm level, in general, PRRS is controlled by the combination of measures adopted, which
include increased levels of biosecurity, so not considered feasible.
At the international level, all MS have competent Veterinary Authorities which ensure compliance
with the relevant EU legislation. International trade continues, so biosecurity measures are generally
considered feasible.
3.1.4.5. Article 7(d)(v) Restrictions on the movement of animals and products
Availability
Parameter 1 – Available movement restriction measures
PRRS is not controlled at EU level, so there are no formal restriction movement measures applied.
In those EU Member/Afﬁliated States free of PRRS (Norway, Sweden, Finland and Switzerland),
controls apply at national level.
Effectiveness
Parameter 2 – Effectiveness of restriction of animal movement in preventing the between farm spread
Pig movements are a major means of PRRSV spread. Movement restrictions and associated
measures contribute signiﬁcantly in reducing spread. However, the virus is also spread by fomites and
by aerosol, so effectiveness is not absolute.
Feasibility
Parameter 3 – Feasibility of restriction of animal movement
Restrictions on animal movements in the form of quarantine and movement subject to testing are
commonly used, so clearly feasible. More stringent application of movement restrictions, consequent
with outbreaks, can lead to overcrowding and may lead to welfare issues.
2 Commission Regulation (EU) No 206/2010 of 12 March 2010 laying down lists of third countries, territories or parts thereof
authorised for the introduction into the European Union of certain animals and fresh meat and the veterinary certiﬁcation
requirements. OJ L 73, 20.3.2010, p. 1–121.
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3.1.4.6. Article 7(d)(vi) Killing of animals
Availability
Parameter 1 – Available methods for killing animals
EU MSs are required to have animal killing capability as part of measures for control of foot-and-
mouth disease (FMD), classical swine fever (CSF), etc. Available measures and associated procedures
to assure animal protection are detailed in Council Regulation (EC) No 1099/20093.
Effectiveness
Parameter 2 – Effectiveness of killing animals (at farm level or within the farm) for reducing /stopping
spread of the disease
Removal of underweight piglets and partial herd slaughter i.e. test and removal (Dee and Molitor,
1998; Dee et al., 2001) are regularly used in control and, in combination with husbandry measures
and biosecurity, are effective in reducing or even eliminating PRRSV from herds.
Feasibility
Parameter 3 – Feasibility of killing animals
In outbreaks in countries free of PRRS, the usual logistical challenges and degree of risk of spread
will depend on speed of slaughter and avoidance of aerosol generation. To reduce risk for fast
spreading of an outbreak, infected herds must be culled within 48 h of diagnosis. Some operational
settings, such as free-ranging pig production systems, may present additional logistical challenges.
3.1.4.7. Article 7(d)(vii) Disposal of carcasses and other relevant animal by-products
Availability
Parameter 1 – Available disposal option
Disposal options for pig carcases and associated wastes are: commercial ﬁxed plant incineration;
rendering (category 1 and 2 of Regulation (EC) No 1069/20094 approved); permitted commercial
landﬁll sites.
Effectiveness
Parameter 2 – Effectiveness of disposal option
Incineration and rendering are closed systems that produce an effective inactivation of PRRSV.
Burial and landﬁll may also be used – PRRSV is relatively labile and would be inactivated relatively
quickly.
Feasibility
Parameter 3 – Feasibility of disposal option
Pigs are regularly disposed of by the methods described. Strict biosecurity during carcase transport
is also required (Hayama et al., 2015).
3.1.5. Article 7(e) The impact of disease prevention and control measures
3.1.5.1. Article 7(e)(i) The direct and indirect costs for the affected sectors and the
economy as a whole
Parameter 1 – Cost of control (e.g. treatment/vaccine, biosecurity)
Very difﬁcult to quantify, since this will depend greatly on the size of the premise, the type of
production and the control method selected. See answers elsewhere in this section for costs of
individual elements.
3 Council Regulation (EC) No 1099/2009 of 24 September 2009 on the protection of animals at the time of killing. OJ L 303,
18.11.2009, p. 1–30.
4 Regulation (EC) No 1069/2009 of the European Parliament and of the Council of 21 October 2009 laying down health rules as
regards animal by-products and derived products not intended for human consumption and repealing Regulation (EC)
No 1774/2002 (Animal by-products Regulation). OJ L 300, 14.11.2009, p. 1–33.
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Parameter 2 – Cost of eradication (culling, compensation)
In Denmark, the most likely national cost of PRRSV has been calculated to be around €15 million
per year, whereas cost of a national eradication program running over a 5-year period, has been
estimated to €120 million. It was estimated that this would give a payback-time for eradication of
around 15 years (Baekbo and Kristensen, 2015). The breakdown of these costs is mainly in testing,
culling of piglets which fail to gain weight, vaccines and culling. No formal programme has been
implemented in Denmark, due to this high cost and the high risk of reinfection - current schemes are
voluntary and no compensation is paid.
Parameter 3 – Cost of surveillance and monitoring
No speciﬁc studies identiﬁed, and difﬁcult to quantify.
Parameter 4 – Trade loss (bans, embargoes, sanctions) by animal product
Data not available. PRRS is not generally reported to OIE and no ofﬁcial controls apply at EU level.
Parameter 5 – Importance of the disease for the affected sector (% loss or € lost compared to
business amount of the sector
The cost of the PRRSV infection in Europe seems not to be very well estimated in most countries –
economic impact of this disease, under ﬁeld conditions, is often overlooked and the few studies
available were often carried out in the USA (Fraile, 2012). Studies in sow herds that experience acute
PRRSV problems have shown a loss of €59 to €379/sow during outbreak in the Netherlands (median
€75) and of €4 to €95/sow in Denmark (median €44).
However, when comparing a large number of chronically infected herds to non-infected herds,
Danish studies show only a marginally reduction in productivity. The piglet mortality was 0.8–0.9%-
point higher and the nursery mortality was 0.4%-point higher in infected herds. No difference was
seen in mortality among ﬁnishers (Baekbo and Kristensen, 2015).
At farm level, an analysis of outbreaks in the Netherlands (Nieuwenhuis et al., 2012) estimated
the economic loss to be between €59 and €379 for one sow per 18-week period outbreak. The
mean loss per sow per outbreak was €126. The costs after the outbreak varied signiﬁcantly from €3
to 160 per sow, due to the different methods used by farmers to tackle PRRSv outbreaks. The
calculated costs in this study correlated with the costs of the initial outbreak in The Netherlands of
€98 per sow.
As well as the direct costs due to the immediate effects an outbreak, the longer-term impacts
of the disease can also be of signiﬁcant cost. In an outbreak in a large farm in Poland, the
expenses dealing with preventing and treating secondary infections, during the 12 months after the
outbreak were on average 60% higher than during the previous year (Pejsak and Markowska-
Daniel, 1997).
3.1.5.2. Article 7(e)(ii) The societal acceptance of disease prevention and control
measures
No social science case studies speciﬁc to PRRS have been identiﬁed. For EU MS with free status,
the programmes were largely industry-driven, on the premise of improved welfare, health animals and
improved productivity – so anticipated to be socially very acceptable.
3.1.5.3. Article 7(e)(iii) The welfare of affected subpopulations of kept and wild animals
Parameter 1 – Welfare impact of control measures on domestic animals
From control of other diseases, e.g. FMD, CSF, movement restrictions may be detrimental to animal
welfare and culling of healthy animals for welfare reasons is seen as a last resort. For PRRS, the lack
of effective vaccines and no DIVA capability may be a signiﬁcant constraint.
Parameter 2 – Wildlife depopulation as control measure
Unlikely to be carried out, given endemicity. Welfare unlikely an issue, given these are a hunted
species in most parts of the EU anyway.
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3.1.5.4. Article 7(e)(iv) The environment and biodiversity
Environment
Parameter 1 – Use and potential residuals of biocides or medical drugs in environmental compartments
(soil, water, feed, manure)
Manufacture and use of disinfectants in the EU must comply with Regulation (EU) No 528/20125.
Biodiversity
Parameter 2 – Mortality in wild species
For wild boar, assumed to be the same as for domestic pigs.
3.2. Assessment according to Article 5 criteria
This section presents the results of the expert judgement on the criteria of Article 5 of the AHL
about PRRS (Table 7). The expert judgement was based on Individual and Collective Behavioural
Aggregation (ICBA) approach described in detail in the opinion on the methodology (EFSA AHAW
Panel, 2017). Experts have been provided with information of the disease fact-sheet mapped into
Article 5 criteria (see supporting information, Annex A), based on that the experts indicate their Y/N or
‘na’ judgement on each criterion of Article 5, and the reasoning supporting their judgement.
The minimum number of judges in the judgement was 12. The expert judgement was conducted
as described in the methodological opinion (EFSA AHAW Panel, 2017). For details on the interpretation
of the questions, see Appendix B of the methodological opinion (EFSA AHAW Panel, 2017).
Table 7: Outcome of the expert judgement on the Article 5 criteria for PRRS
Criteria to be met by the disease:
According to AHL, a disease shall be included in the list referred to in point (b) of paragraph 1 of
Article 5 if it has been assessed in accordance with Article 7 and meets all of the following
criteria
Final
outcome
A(i) The disease is transmissible Y
A(ii) Animal species are either susceptible to the disease or vectors and reservoirs thereof
exist in the Union
Y
A(iii) The disease causes negative effects on animal health or poses a risk to public health due
to its zoonotic character
Y
A(iv) Diagnostic tools are available for the disease Y
A(v) Risk-mitigating measures and, where relevant, surveillance of the disease are effective
and proportionate to the risks posed by the disease in the Union
Y
At least one criterion to be met by the disease:
In addition to the criteria set out above at points A(i)–A(v), the disease needs to fulﬁl at least one of the
following criteria
B(i) The disease causes or could cause signiﬁcant negative effects in the Union on animal
health, or poses or could pose a signiﬁcant risk to public health due to its zoonotic
character
Y
B(ii) The disease agent has developed resistance to treatments and poses a signiﬁcant danger
to public and/or animal health in the Union
na
B(iii) The disease causes or could cause a signiﬁcant negative economic impact affecting
agriculture or aquaculture production in the Union
Y
B(iv) The disease has the potential to generate a crisis or the disease agent could be used for
the purpose of bioterrorism
N
B(v) The disease has or could have a signiﬁcant negative impact on the environment,
including biodiversity, of the Union
N
Colour code: green = consensus (Yes/No), yellow = no consensus (NC), red = not applicable (na), i.e. insufﬁcient evidence or
irrelevant to judge.
5 Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available
on the market and use of biocidal products. OJ L 167, 27.6.2012, p. 1–123.
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3.2.1. Outcome of the assessment of PRRS according to criteria of Article 5(3) of
the AHL on its eligibility to be listed
As from the legal text of the AHL, a disease is considered eligible to be listed as laid down in Article
5 if it fulﬁls all criteria of the ﬁrst set from A(i) to A(v) and at least one of the second set of criteria
from B(i) to B(v). According to the assessment methodology (EFSA AHAW Panel et al., 2017), a
criterion is considered fulﬁlled when the outcome is ‘Yes’. According to the results shown in Table 7,
PRRS complies with all criteria of the ﬁrst set and with two criteria of the second set, therefore it is
considered eligible to be listed as laid down in Article 5 of the AHL.
3.3. Assessment according to Article 9 criteria
This section presents the results of the expert judgement on the criteria of Annex IV referring to
categories as in Article 9 of the AHL about PRRS (Tables 8, 9, 10, 11 and 12). The expert judgement
was based on ICBA approach described in detail in the opinion on the methodology. Experts have been
provided with information of the disease fact-sheet mapped into Article 9 criteria (see supporting
information, Annex A), based on that the experts indicate their Y/N or ‘na’ judgement on each criterion
of Article 9, and the reasoning supporting their judgement. The minimum number of judges in the
judgement was 12. The expert judgement was conducted as described in the methodological opinion
(EFSA AHAW Panel, 2017). For details on the interpretation of the questions see Appendix B of the
methodological opinion (EFSA AHAW Panel, 2017).
Table 8: Outcome of the expert judgement related to the criteria of Section 1 of Annex IV
(category A of Article 9) for PRRS (CI=current impact; PI=potential impact)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is not present in the territory of the Union OR present only in exceptional
cases (irregular introductions) OR present in only in a very limited part of the territory
of the Union
N
2.1 The disease is highly transmissible NC
2.2 There be possibilities of airborne or waterborne or vector-borne spread Y
2.3 The disease affects multiple species of kept and wild animals OR single species of kept
animals of economic importance
Y
2.4 The disease may result in high morbidity and signiﬁcant mortality rates Y
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health,
including epidemic or pandemic potential OR possible signiﬁcant threats to food safety
N
4(CI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
Y
4(PI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
Y
5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b)(CI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
Y
5(b)(PI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
Y
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
N
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
N
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Table 9: Outcome of the expert judgement related to the criteria of Section 2 of Annex IV
(category B of Article 9) for PRRS (CI=current impact; PI=potential impact)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is present in the whole OR part of the Union territory with an endemic
character AND (at the same time) several Member States or zones of the Union are
free of the disease
NC
2.1 The disease is moderately to highly transmissible NC
2.2 There be possibilities of airborne or waterborne or vector-borne spread Y
2.3 The disease affects single or multiple species Y
2.4 The disease may result in high morbidity with in general low mortality N
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health,
including epidemic potential OR possible signiﬁcant threats to food safety
N
4(CI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
Y
4(PI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
Y
5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b)(CI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
Y
5(b)(PI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
Y
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
N
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
N
5(d)(CI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
N
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
N
Colour code: green = consensus (Yes/No), yellow = no consensus (NC).
5(d)(CI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection of
endangered species or breeds, including the possible disappearance or long-term damage to
those species or breeds
N
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection of
endangered species or breeds, including the possible disappearance or long-term damage to
those species or breeds
N
Colour code: green = consensus (Yes/No), yellow = no consensus (NC).
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Table 10: Outcome of the expert judgement related to the criteria of Section 3 of Annex IV
(category C of Article 9) for PRRS (CI = current impact; PI = potential impact)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is present in the whole OR part of the Union territory with an endemic
character
Y
2.1 The disease is moderately to highly transmissible NC
2.2 The disease is transmitted mainly by direct or indirect transmission Y
2.3 The disease affects single or multiple species Y
2.4 The disease usually does not result in high morbidity and has negligible or no mortality
AND often the most observed effect of the disease is production loss
N
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health, or
possible signiﬁcant threats to food safety
N
4(CI) The disease has a signiﬁcant impact on the economy of parts of the Union, mainly
related to its direct impact on certain types of animal production systems
N
4(PI) The disease has a signiﬁcant impact on the economy of parts of the Union, mainly
related to its direct impact on certain types of animal production systems
N
5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b)(CI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
Y
5(b)(PI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
Y
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
N
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
N
5(d)(CI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
N
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
N
Colour code: green = consensus (Yes/No), yellow = no consensus (NC).
Table 11: Outcome of the expert judgement related to the criteria of Section 4 of Annex IV
(category D of Article 9) for PRRS
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
D The risk posed by the disease in question can be effectively and proportionately mitigated
by measures concerning movements of animals and products in order to prevent or limit its
occurrence and spread
Y
The disease fulﬁls criteria of Sections 1, 2, 3 or 5 of Annex IV of AHL Y
Colour code: green = consensus (Yes/No).
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3.3.1. Non-consensus questions
This section displays the assessment related to each criterion of Annex IV referring to the
categories of Article 9 of the AHL where no consensus was achieved in form of tables (Tables 13 and
14). The proportion of Y, N or ‘na’ answers are reported, followed by the list of different supporting
views for each answer.
Reasoning supporting the judgement
Supporting Yes for 1 (cat.B):
• Four European countries including two MSs (Sweden, Finland, Norway and Switzerland) are
free from the disease, thus indicating that it is possible to demonstrate freedom of disease.
Supporting No for 1 (cat.B):
• Only two MSs, thus not several, are free from the disease.
Reasoning supporting the judgement
Supporting Yes for 2.1 (cat.A):
• The disease generally spreads to all animals in a herd unit and easily spreads between herds
by various routes including direct, indirect (e.g. semen) and airborne routes.
Supporting Yes for 2.1 (cat.B,C):
• The transmissibility varies considerably depending on a number of factors, including the strain/
virulence of the virus involved, the infection dose, and route, as well as the age, immune
response and presence of other pathogens in the pig.
Table 12: Outcome of the expert judgement related to the criteria of Section 5 of Annex IV
(category E of Article 9) for PRRS
Diseases in category E need to fulﬁl criteria of Sections 1, 2 or 3 of Annex IV of AHL
and/or the following:
Final
outcome
E Surveillance of the disease is necessary for reasons relating to animal health, animal welfare,
human health, the economy, society or the environment (If a disease fulﬁls the criteria as in
Article 5, thus being eligible to be listed, consequently category E would apply.)
Y
Colour code: green = consensus (Yes/No).
Table 13: Outcome of the expert judgement related to criterion 1 of Article 9
Question
Final
outcome
Response
Y
(%)
N
(%)
na
(%)
1(cat.B) The disease is present in the whole OR part of the Union territory
with an endemic character AND (at the same time) several
Member States or zones of the Union are free of the disease
NC 83 17 0
NC: non-consensus; number of judges: 12.
Table 14: Outcome of the expert judgement related to criterion 2.1 of Article 9
Question Final outcome
Response
Y
(%)
N
(%)
na
(%)
2.1(cat.A) The disease is highly transmissible NC 58 42 0
2.1(cat.B,C) The disease is moderately to highly transmissible NC 42 58 0
NC: non-consensus; number of judges: 12.
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3.3.2. Outcome of the assessment of criteria in Annex IV for PRRS for the
purpose of categorisation as in Article 9 of the AHL
As from the legal text of the AHL, a disease is considered ﬁtting in a certain category (A, B, C, D or
E corresponding to point (a) to point (e) of Article 9(1) of the AHL) if it is eligible to be listed for Union
intervention as laid down in Article 5(3) and fulﬁls all criteria of the ﬁrst set from 1 to 2.4 and at least
one of the second set of criteria from 3 to 5(d) as shown in Tables 8–12. According to the assessment
methodology (EFSA AHAW Panel, 2017), a criterion is considered fulﬁlled when the outcome is ‘Yes’.
With respect to different type of impact where the assessment is divided into current and potential
impact, a criterion will be considered fulﬁlled if at least one of the two outcomes is ‘Y’ and, in case of
no ‘Y’, the assessment is inconclusive if at least one outcome is ‘NC’.
A description of the outcome of the assessment of criteria in Annex IV for PRRS for the purpose of
categorisation as in Article 9 of the AHL is presented in Table 15.
According to the assessment here performed, PRRS complies with the following criteria of the
sections 1–5 of Annex IV of the AHL for the application of the disease prevention and control rules
referred to in points (a)–(e) of Article 9(1):
1) To be assigned to category A, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment PRRS complies with criteria 2.2, 2.3 and 2.4
but not with criterion 1 and the assessment is inconclusive on compliance with criterion 2.1.
To be eligible for category A, a disease needs to comply additionally with one of the criteria
of the second set (3, 4, 5a–d) and PRRS complies with criteria 4 and 5b but not with criteria
3, 5a, 5c and 5d.
2) To be assigned to category B, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment PRRS complies with criteria 2.2 and 2.3, but
not with criterion 2.4 and the assessment is inconclusive on compliance with criteria 1 and
2.1. To be eligible for category B, a disease needs to comply additionally with one of the
criteria of the second set (3, 4, 5a–d) and PRRS complies with criteria 4 and 5b but not with
criteria 3, 5a, 5c and 5d.
3) To be assigned to category C, a disease needs to comply with all criteria of the ﬁrst set (1, 2.1–2.4)
and according to the assessment PRRS complies with criteria 1, 2.2 and 2.3 but not with
criterion 2.4 and the assessment is inconclusive on compliance with criterion 2.1. To be
eligible for category C, a disease needs to comply additionally with one of the criteria of the
second set (3, 4, 5a–d) and PRRS complies with criterion 5b but not with criteria 3, 4, 5a, 5c
and 5d.
4) To be assigned to category D, a disease needs to comply with criteria of sections 1, 2, 3 or 5
of Annex IV of the AHL and with the speciﬁc criterion D of section 4, with which PRRS
complies.
Table 15: Outcome of the assessment of criteria in Annex IV for PRRS for the purpose of
categorisation as in Article 9 of the AHL
Category
Article 9 criteria
1° set of criteria 2° set of criteria
1 2.1 2.2 2.3 2.4 3 4 5a 5b 5c 5d
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5) To be assigned to category E, a disease needs to comply with criteria of sections 1, 2 or 3 of
Annex IV of the AHL and/or the surveillance of the disease is necessary for reasons relating
to animal health, animal welfare, human health, the economy, society or the environment.
The latter is applicable if a disease fulﬁls the criteria as in Article 5, with which PRRS
complies.
3.4. Assessment of Article 8
This section presents the results of the assessment on the criteria of Article 8(3) of the AHL about
PRRS. The Article 8(3) criteria are about animal species to be listed, as it reads below:
‘3. Animal species or groups of animal species shall be added to this list if they are affected or if
they pose a risk for the spread of a speciﬁc listed disease because:
a) they are susceptible for a speciﬁc listed disease or scientiﬁc evidence indicates that such
susceptibility is likely; or
b) they are vector species or reservoirs for that disease, or scientiﬁc evidence indicates that such
role is likely’.
For this reason the assessment on Article 8 criteria is based on the evidence as extrapolated from
the relevant criteria of Article 7, i.e. the ones related to susceptible and reservoir species or routes of
transmission, which cover also the possible role of biological or mechanical vectors.6 According to the
mapping, as presented in Table 5, section 3.2 of the scientiﬁc opinion on the ad hoc methodology
(EFSA AHAW Panel et al., 2017), the main animal species to be listed for PRRS according to the criteria
of Article 8(3) of the AHL are as displayed in Table 16.
4. Conclusions
TOR 1: for each of those diseases an assessment, following the criteria laid down in Article 7 of
the AHL, on its eligibility of being listed for Union intervention as laid down in Article 5(3) of the AHL;
• According to the assessment here performed, PRRS complies with all criteria of the ﬁrst set
and with two criteria of the second set and therefore can be considered eligible to be listed for
Union intervention as laid down in Article 5(3) of the AHL.
TOR 2a: for each of the diseases which was found eligible to be listed for Union intervention, an
assessment of its compliance with each of the criteria in Annex IV to the AHL for the purpose of
categorisation of diseases in accordance with Article 9 of the AHL;
• According to the assessment here performed, PRRS complies with the criteria as in Sections 4
and 5 of Annex IV of the AHL, for the application of the disease prevention and control rules
referred to in points (d) and (e) of Article 9(1) of the AHL.
TOR 2b: for each of the diseases which was found eligible to be listed for Union intervention, a list
of animal species that should be considered candidates for listing in accordance with Article 8 of the
AHL.
• According to the assessment here performed, the animal species that can be considered to be
listed for PRRS according to Article 8(3) of the AHL are domestic pigs and wild boar, as
reported in Table 16 in Section 3.4 of the present document.
Table 16: Main animal species to be listed for PRRS according to criteria of Article 8 (source: data
reported in Section 3.1.1.1)
Class Order Family Genus/species
Susceptible Mammalia Artiodactyla Suidae Sus scrofa
Reservoir None
Vectors None
6 A vector is a living organism that transmits an infectious agent from an infected animal to a human or another animal. Vectors
are frequently arthropods. Biological vectors may carry pathogens that can multiply within their bodies and be delivered to new
hosts, usually by biting. In mechanical vectors the pathogens do not multiply within the vector, which usually remains infected
for shorter time than in biological vectors.
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